Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer
-
- Yoon Young Choi
- Department of Surgery, Yonsei University Health System, Seoul, South Korea
-
- Hyunki Kim
- Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea
-
- Su-Jin Shin
- Department of Pathology, College of Medicine, Hanyang University, Seoul, South Korea
-
- Ha Yan Kim
- Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, South Korea
-
- Jinae Lee
- Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, South Korea
-
- Han-Kwang Yang
- Department of Surgery and Cancer Research Institute, Seoul, South Korea
-
- Woo Ho Kim
- Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea
-
- Young-Woo Kim
- Center for Gastric Cancer, National Cancer Center, Goyang-si, Gyeonggi-do, South Korea
-
- Myeong-Cherl Kook
- Center for Gastric Cancer, National Cancer Center, Goyang-si, Gyeonggi-do, South Korea
-
- Young Kyu Park
- Department of Surgery, Chonnam National University Hwasun Hospital, Jeonnam, South Korea
-
- Hyung-Ho Kim
- Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, South Korea
-
- Hye Seung Lee
- Department of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, South Korea
-
- Kyung Hee Lee
- Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea
-
- Mi Jin Gu
- Department of Pathology, Yeungnam University College of Medicine, Daegu, South Korea
-
- Seung Ho Choi
- Department of Surgery, Gangnam Severance Hospital, Seoul, South Korea
-
- SoonWon Hong
- Department of Pathology, Gangnam Severance Hospital, Seoul, South Korea
-
- Jong Won Kim
- Department of Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, South Korea
-
- Woo Jin Hyung
- Department of Surgery, Yonsei University Health System, Seoul, South Korea
-
- Sung Hoon Noh
- Department of Surgery, Yonsei University Health System, Seoul, South Korea
-
- Jae-Ho Cheong
- Department of Surgery, Yonsei University Health System, Seoul, South Korea
Bibliographic Information
- Other Title
-
- Post Hoc Analysis of the CLASSIC Randomized Controlled study
Description
<jats:sec> <jats:title>Objective:</jats:title> <jats:p>We investigated microsatellite instability (MSI) status and programed cell death ligand 1 (PD-L1) expression as predictors of prognosis and responsiveness to chemotherapy for stage II/III gastric cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Background:</jats:title> <jats:p>The clinical implications of MSI status and PD-L1 expression in gastric cancer have not been well-elucidated.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Tumor specimens and clinical information were collected from patients enrolled in the CLASSIC trial—a randomized controlled study of capecitabine plus oxaliplatin-based adjuvant chemotherapy. Five quasi-monomorphic mononucleotide markers were used to assess tumor MSI status. PD-L1 expressions of tumor and stromal immune cells were evaluated using immunohistochemistry.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Of 592 patients, 40 (6.8%) had MSI-high (MSI-H) tumors. Among 582 patients available for immunohistochemistry evaluation, PD-L1 was positive in tumor cells (tPD-L1) of 16 patients (2.7%) and stromal immune cells (sPD-L1) of 165 patients (28.4%). Multivariable analysis of disease-free survival (DFS) showed that MSI-H and sPD-L1-positivity were independent prognostic factors [hazard ratio 0.301 (0.123–0.736), 0.714 (0.514–0.991); <jats:italic toggle="yes">P</jats:italic> = 0.008, 0.044), as were receiving chemotherapy, age, tumor grade, and TNM stage. Although adjuvant chemotherapy improved DFS in the microsatellite-stable (MSS) group (5-year DFS: 66.8% vs 54.1%; <jats:italic toggle="yes">P</jats:italic> = 0.002); no benefit was observed in the MSI-H group (5-year DFS: 83.9% vs 85.7%; <jats:italic toggle="yes">P</jats:italic> = 0.931). In the MSS group, sPD-L1-negative patients, but not sPD-L1-positive patients, had significant survival benefit from adjuvant chemotherapy compared with surgery only (5-year DFS: 66.1% vs 50.7%; <jats:italic toggle="yes">P</jats:italic> = 0.001).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>MSI status and PD-L1 expression are clinically actionable biomarkers for stratifying patients and predicting benefit from adjuvant chemotherapy after D2 gastrectomy for stage II/III gastric cancer.</jats:p> </jats:sec>
Journal
-
- Annals of Surgery
-
Annals of Surgery 270 (2), 309-316, 2019-08
Ovid Technologies (Wolters Kluwer Health)
- Tweet
Details 詳細情報について
-
- CRID
- 1364233270100072576
-
- ISSN
- 15281140
- 00034932
-
- Data Source
-
- Crossref